drugset
drugset / Trial / NCT03748680

IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer

NCT03748680 ↗

Phase 2 Unknown 64 enrolled Karen-Lise Garm Spindler
RandomizedParallel-groupOpen-labelTreatment

Summary

A open label 1:1 randomized phase II exploratory study investigating adjuvant therapy in patients with molecular biologically detectable residual disease after primary resection for localized colorectal tumors.

Timeline

Start
2018-10-01
Primary completion
2023-10-01
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 —
Subject Leucovorin Small molecule 400 mg/m2 —
Subject Oxaliplatin Small molecule 85 mg/m2 —
Subject Oxaliplatin Small molecule 130 mg/m2 —
Subject fluorouracil Small molecule 2400 mg/m2 —

Indications

colorectal cancer